Nielsen BioSciences Announces Expanded CANDIN License Agreement with Maruho Co. Ltd.
Expansion of licensing agreement extends CANDIN’s development to key Asian growth markets including China, South Korea and Taiwan–and broadens the collaboration... Read more.
United Bankshares, Inc. Announces Record Earnings for the Third Quarter of 2025
WASHINGTON & CHARLESTON, W.Va.–(BUSINESS WIRE)–United Bankshares, Inc. (NASDAQ: UBSI) (“United”), today reported record earnings for the third... Read more.
Union Pacific Reports Third Quarter 2025 Results
Diluted earnings per share (EPS) of $3.01 and adjusted diluted EPS* of $3.08 Operating ratio (OR) of 59.2% and adjusted OR* of 58.5% Operating revenue increased... Read more.
Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare
45 percent of 18- to 29-year-olds do not have a primary care physician.1 For patients with chronic conditions, the consequences can be significant.2 Resources for... Read more.
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
Conference Call to be Held at 8:30 a.m. ET CHICAGO–(BUSINESS WIRE)–Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company... Read more.
Acacia Research to Release Third Quarter 2025 Financial Results on November 5, 2025
NEW YORK–(BUSINESS WIRE)–Acacia Research Corporation (NASDAQ: ACTG) (“Acacia” or the “Company”), which acquires and operates businesses across... Read more.
World Acceptance Corporation Reports Fiscal 2026 Second Quarter Results
GREENVILLE, S.C.–(BUSINESS WIRE)–$WRLD–World Acceptance Corporation (NASDAQ: WRLD) today reported financial results for its second quarter of fiscal... Read more.
U.S. Ski & Snowboard and iCapital® Announce Partnership to Champion Excellence of Teams
PARK CITY, Utah & NEW YORK–(BUSINESS WIRE)–#alternatives–U.S. Ski & Snowboard, the national governing body of Olympic and Paralympic ski... Read more.
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
No targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase... Read more.
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after... Read more.